Janux Therapeutics is developing T cell engagers to treat tumors, with promising Phase 1 data showing potential for blockbuster success. Their technology, TRACTr, aims to overcome limitations of current therapies by reducing toxicity and increasing efficacy. Their lead program, JANX007, has shown positive results in treating prostate cancer, with significant declines in PSA levels without severe side effects. JANX0008 has also shown promise in treating solid tumors, with some patients experiencing partial responses. With potential peak sales of $1.5 billion, Janux’s therapies have multi-blockbuster potential, increasing optimism for their success in the future.
Source link
Janux Rides Its TRACTr to Validation in Prostate Cancer and More Solid Tumors
